Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data suggests asciminib may help some leukemia patients

NCT ID NCT07644351

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study reviewed medical records of 37 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who took asciminib because other treatments stopped working or caused side effects. Researchers wanted to see how many patients achieved complete remission within three months. The study is completed and provides real-world insight, but it was small and not a controlled trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
asciminib
What this could lead to
If results are positive, asciminib could offer a new treatment option for adults with Ph+ ALL who have run out of other choices.
What could go wrong
This is a small, retrospective chart review (37 patients), not a controlled trial. Results may not apply to all patients, and safety data is limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia leukemia, acute lymphocytic, susceptibility to, 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

  • Novartis Investigative Site

    Boston, Massachusetts, 02115, United States

  • Novartis Investigative Site

    Sydney, New South Wales, 2145, Australia

  • Novartis Investigative Site

    Montreal, H1T 2M4, Canada

  • Novartis Investigative Site

    Hong Kong, China

  • Novartis Investigative Site

    Le Chesnay, 78150, France

  • Novartis Investigative Site

    Ramat Gan, 52621, Israel

  • Novartis Investigative Site

    Ascoli Piceno, 63100, Italy

  • Novartis Investigative Site

    Bari, 70124, Italy

  • Novartis Investigative Site

    Catania, 95123, Italy

  • Novartis Investigative Site

    Cuneo, 12100, Italy

  • Novartis Investigative Site

    Pescara, 65124, Italy

  • Novartis Investigative Site

    Torino, 10126, Italy

  • Novartis Investigative Site

    Rotterdam, 3015, Netherlands

  • Novartis Investigative Site

    Islamabad, 44000, Pakistan

  • Novartis Investigative Site

    Rawalpindi, 46000, Pakistan

  • Novartis Investigative Site

    Bialystok, 15-276, Poland

  • Novartis Investigative Site

    Madrid, 28006, Spain

  • Novartis Investigative Site

    London, SE5 9RS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.